MC2 Therapeutics’ dry eye treatment demonstrates positive phase 2 results

MC2-03, a treatment candidate from MC2 Therapeutics, showed clinical improvement in moderate to severe dry eye patients in the phase 2 MC2-03-C1 Northern Lights trial, according to a press release.
MC2-03 (PADciclo) is an eye drop containing ciclosporin and formulated using the company’s proprietary PAD technology.
The randomized, double-masked, parallel arms, controlled 6-month study included 263 dry eye patients in two active treatment arms, MC2-03 0.06% ciclosporin and MC2-03 0.03% ciclosporin, which were compared with two control arms, MC2-03 vehicle and lubricant, the release said.

Full Story →